Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Johnson & Johnson

M. Socinski, D. Waterhouse

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Johnson & Johnson

J. Heymach, M. Das

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Year in Review: Lung Cancer

Balazs Halmos

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

Cancer Screening Molecular Tools

Fengting Yan

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

Staging Disease: How Oncologists Stage NSCLC

GRACE

I. Dagogo-Jack, M. Das, C. Jeffrey Yang

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical Implicat…

Insights from 2023 ASCO® Annual Meeting

J. West

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Yale Cancer Center

P. Janne

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

2024 Updates on the Fast-Changing NSCLC Landscape

Total Health

R. Osarogiagbon

NSCLC & Targeted Therapy: A Brief Overview and Update in the Metasta…

Memorial Sloan Kettering Cancer Center

M. Hwang